Financial Performance - Operating revenue for the first quarter rose by 16.58% to CNY 1,606,578,185.99 year-on-year [12]. - Net profit attributable to shareholders increased by 8.31% to CNY 92,671,901.89 compared to the same period last year [12]. - Basic and diluted earnings per share increased by 5.88% to CNY 0.18 per share [12]. - Total operating revenue for Q1 2014 was CNY 1,606,578,185.99, an increase of 16.6% compared to CNY 1,378,134,897.35 in Q1 2013 [14]. - Net profit attributable to shareholders of the parent company was CNY 92,671,901.89, a rise of 7.4% from CNY 85,561,421.45 in Q1 2013 [37]. - The company reported a total comprehensive income of CNY 136,464,388.03 for Q1 2014, compared to CNY 129,913,289.19 in Q1 2013 [37]. Cash Flow - Cash flow from operating activities was CNY 157,808,713.47, a significant recovery from a negative cash flow of CNY -90,998,105.56 in the previous year [12]. - Cash inflow from operating activities amounted to CNY 140,753,593.30, an increase of 50.8% compared to CNY 93,273,822.45 in the previous period [46]. - Cash outflow from investment activities totaled CNY 71,673,200.44, significantly reduced from CNY 289,270,350.47 in the previous period [46]. - Net cash flow from investment activities was -CNY 68,700,705.52, an improvement from -CNY 285,895,068.33 year-over-year [46]. - Financing activities generated a net cash inflow of CNY 124,768,032.32, down from CNY 483,808,498.35 in Q1 2013 [43]. - Net cash flow from financing activities decreased to CNY 46,422,943.14 from CNY 305,527,646.83, a decline of 84.8% [46]. Assets and Liabilities - Total assets increased by 3.81% to CNY 10,076,909,264.40 compared to the end of the previous year [11]. - The company's total assets amounted to CNY 1,007,690.93 million, an increase of CNY 36,990.43 million or 3.81% compared to the end of 2013 [19]. - Total liabilities increased, with accounts payable rising by 40.54% compared to the beginning of the period, attributed to the use of bank acceptance bills [19]. - Total liabilities rose to ¥4,912,162,048.41 from ¥4,626,658,965.19, which is an increase of about 6.2% [31]. - Total equity increased to ¥5,164,747,215.99 from ¥5,080,346,062.41, indicating a growth of about 1.7% [31]. Shareholder Information - The total number of shareholders reached 19,360 [15]. - The largest shareholder, Wuhan Contemporary Science and Technology Industry Group, holds 17.07% of the shares [15]. Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to CNY 4,948,274.90 during the quarter [13]. - The company reported a total of CNY 3,676,624.11 in net non-recurring gains and losses [13]. Investment and Management Expenses - The company's investment income decreased by 77.98% year-on-year, primarily due to the previous year's dividend income from financial institutions [19]. - The company's management expenses increased by 30.36% year-on-year, mainly due to rising costs of labor and daily expenses [19].

Dividend and Profit Distribution - The board proposed a cash dividend of 1.20 RMB per 10 shares, totaling 63,453,266.64 RMB based on the total share capital of 528,777,222 shares as of the end of 2013[9]. - The cash dividend distribution for 2013 is proposed at ¥1.20 per 10 shares, totaling ¥63,453,266.64[135]. - The cash dividend payout ratio for 2013 is 15.19% of the net profit attributable to shareholders[137]. - The cash dividend policy stipulates that the company will distribute at least 10% of the net profit attributable to shareholders in cash annually, ensuring stable returns for investors[126]. - The company has maintained a consistent cash dividend policy, distributing dividends every year since its listing[132]. - The company will maintain a continuous and stable profit distribution policy, with cumulative cash distributions over the last three years not less than 30% of the average annual distributable profit[126]. Financial Performance - The company achieved operating revenue of ¥6,010,211,397.82 in 2013, representing a 13.04% increase compared to ¥5,317,093,009.73 in 2012[30]. - Net profit attributable to shareholders was ¥417,780,076.54, a 2.90% increase from ¥405,990,787.59 in the previous year[30]. - The net profit after deducting non-recurring gains and losses was ¥395,524,806.29, reflecting a 19.50% increase from ¥330,996,110.12 in 2012[30]. - The net cash flow from operating activities surged by 189.20% to ¥498,216,711.17, up from ¥172,273,069.29 in 2012[30]. - The company's total assets increased by 23.48% to ¥9,707,005,027.60 at the end of 2013, compared to ¥7,861,257,547.57 at the end of 2012[30]. - Basic earnings per share rose to ¥0.83, up from ¥0.82 in 2012[32]. - The weighted average return on equity decreased by 2.35 percentage points to 11.92% in 2013[32]. - The company achieved a net profit of ¥601,250,236.75 in 2013, with a net profit attributable to shareholders of ¥417,780,076.54[133]. Business Operations and Strategy - The company has maintained its main business without changes since its listing in 1997[23]. - The company emphasizes the importance of risk awareness regarding industry environment, policy risks, and operational management risks[14]. - The company is focusing on new drug development and international business expansion as part of its strategic plan[68]. - The company is actively expanding its international business and increasing R&D investments to maintain growth momentum[77]. - The company is focusing on enhancing its production capabilities and compliance with international standards[112]. - The company is committed to innovation and aims to accelerate the development and launch of new products[112]. - The company is actively seeking to enter essential drug directories to capitalize on healthcare reforms[116]. - The company is navigating risks related to industry policy changes and market access for its products[115]. Research and Development - The company’s R&D expenditure totaled CNY 230.37 million, accounting for 3.83% of operating revenue, with a year-on-year growth of 8.57%[58][59]. - Research and development expenditures for 2011, 2012, and 2013 were ¥156 million, ¥212 million, and ¥230 million respectively, indicating a focus on innovation[134]. - The company plans to invest in new product development and technology, enhancing its research capabilities and protecting intellectual property[119]. Shareholder Structure and Equity - The first major shareholder, Wuhan Contemporary Technology Industry Group Co., Ltd., held 17.07% of the company's shares as of December 31, 2013[24]. - The total number of shareholders at the end of the reporting period was 18,327, compared to 25,147 five trading days before the annual report disclosure[189]. - The largest shareholder, Wuhan Contemporary Technology Industry Group Co., Ltd., held 90,287,061 shares, representing 17.07% of total shares, with 83,390,510 shares pledged[189]. - The top ten unrestricted shareholders collectively held 139,000,000 shares, with Wuhan Contemporary Technology Industry Group Co., Ltd. holding the largest share of 57,854,304[190]. - The company has commitments regarding the non-transfer of shares for a period of 36 months following the non-public offering, ensuring stability in shareholding[193]. Financial Management and Investments - The company established a multi-level financing system, raising approximately ¥1 billion through a private placement and issuing ¥800 million in short-term financing bonds[41]. - The company completed a non-public offering, raising 1,026.64 million RMB, a year-on-year increase of 3,191.13%[62]. - The company raised ¥1,024.67 million through a private placement in August 2013, with a net amount of ¥985.33 million after deducting issuance costs[88]. - The total amount of funds raised for projects was CNY 48,369.24 million, with actual cumulative investment reaching CNY 56,202.85 million[90]. - The company completed the repayment of bank loans and utilized funds for working capital, with a total of CNY 13,630.61 million used[90]. Market Performance and Sales - The company reported a 31.82% growth in its core pharmaceutical business, contributing significantly to overall profit growth[39]. - Pharmaceutical products accounted for 98.01% of total revenue, with anesthetics generating CNY 1,363.25 million, representing 22.68% of total revenue[45][46]. - The company’s sales expenses increased by 23.29% to CNY 1,030.30 million, primarily due to enhanced marketing efforts and increased personnel costs[56]. - The company’s gross profit margin improved, with the cost of raw materials rising by 41.01% to CNY 650.94 million, reflecting the expansion of production capacity[52]. Compliance and Risk Management - The company received a standard unqualified audit report from Da Xin Accounting Firm[8]. - The company emphasizes the importance of managing costs and developing new products to maintain competitiveness amid potential regulatory changes in the pharmaceutical market[117]. - The company is actively monitoring foreign exchange market trends to mitigate risks associated with fluctuations in the RMB exchange rate[117]. - The company has established a comprehensive investment decision-making mechanism to mitigate risks associated with project investments, considering market conditions and macroeconomic factors[120]. Corporate Social Responsibility - The company emphasizes social responsibility and has actively participated in various charitable activities[138].